Certain A Shares of Zhejiang Haisen Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 10-APR-2026. These A Shares will be under lockup for 1103 days starting from 3-APR-2023 to 10-APR-2026.
Details:
The company?s actual controllers Wang Shiyue, Wang Yuxiao and Guo Haiyan promised that, within 36 months from the listing date of Zhejiang Haisen Pharmaceutical Co., Ltd., the shares of Zhejiang Haisen Pharmaceutical Co., Ltd. held by the person issued before the IPO will not be transferred or entrusted to others for management; also, Zhejiang Haisen Pharmaceutical Co., Ltd. will not repurchase this part of the shares. Within 6 months after the listing of Zhejiang Haisen Pharmaceutical Co., Ltd., if the closing price of the company?s stock is lower than the issue price for 20 consecutive trading days or if the closing price at the end of 6 months after listing is lower than the issue price, the lock-up period of the shares held by the person in Zhejiang Haisen Pharmaceutical Co., Ltd. will be automatically extended for 6 months. In case of ex-rights and ex-dividend events, the above issue price shall be adjusted accordingly. During the person?s tenure as director and senior management of Zhejiang Haisen Pharmaceutical Co., Ltd., the person will report the shares held in Zhejiang Haisen Pharmaceutical Co., Ltd. and its changes to Zhejiang Haisen Pharmaceutical Co., Ltd. The shares transferred by the person in each year shall not exceed 25% of the total number of shares held by the person in Zhejiang Haisen Pharmaceutical Co., Ltd. Within 6 months after resignation, the shares of Zhejiang Haisen Pharmaceutical Co., Ltd. held by the person shall not be transferred.
The company?s holding shareholder, Zhejiang Haisen Holdings Co., Ltd., promised that, within 36 months from the listing date of Zhejiang Haisen Pharmaceutical Co., Ltd., the shares of Zhejiang Haisen Pharmaceutical Co., Ltd. held by the person issued before the IPO will not be transferred or entrusted to others for management; also, Zhejiang Haisen Pharmaceutical Co., Ltd. will not repurchase this part of the shares. Within 6 months after the listing of Zhejiang Haisen Pharmaceutical Co., Ltd., if the closing price of the company?s stock is lower than the issue price for 20 consecutive trading days or if the closing price at the end of 6 months after listing is lower than the issue price, the lock-up period of the shares held by the person in Zhejiang Haisen Pharmaceutical Co., Ltd. will be automatically extended for 6 months. In case of ex-rights and ex-dividend events, the above issue price shall be adjusted accordingly.
The shareholder controlled by the company?s holding shareholder, Dongyang Taiqi Investment Management Partnership Enterprise (Limited Partnership) promised that, within 36 months from the listing date of Zhejiang Haisen Pharmaceutical Co., Ltd., the shares of Zhejiang Haisen Pharmaceutical Co., Ltd. held by the person issued before the IPO will not be transferred or entrusted to others for management; also, Zhejiang Haisen Pharmaceutical Co., Ltd. will not repurchase this part of the shares. Within 6 months after the listing of Zhejiang Haisen Pharmaceutical Co., Ltd., if the closing price of the company?s stock is lower than the issue price for 20 consecutive trading days or if the closing price at the end of 6 months after listing is lower than the issue price, the lock-up period of the shares held by the person in Zhejiang Haisen Pharmaceutical Co., Ltd. will be automatically extended for 6 months. In case of ex-rights and ex-dividend events, the above issue price shall be adjusted accordingly.
The relatives of the company?s actual controller and company shareholder Wang Dongyan promised that, within 36 months from the listing date of Zhejiang Haisen Pharmaceutical Co., Ltd., the shares of Zhejiang Haisen Pharmaceutical Co., Ltd. held by the person issued before the IPO will not be transferred or entrusted to others for management; also, Zhejiang Haisen Pharmaceutical Co., Ltd. will not repurchase this part of the shares. Within 6 months after the listing of Zhejiang Haisen Pharmaceutical Co., Ltd., if the closing price of the company?s stock is lower than the issue price for 20 consecutive trading days or if the closing price at the end of 6 months after listing is lower than the issue price, the lock-up period of the shares held by the person in Zhejiang Haisen Pharmaceutical Co., Ltd. will be automatically extended for 6 months. In case of ex-rights and ex-dividend events, the above issue price shall be adjusted accordingly. During the person?s tenure as director and senior management of Zhejiang Haisen Pharmaceutical Co., Ltd., the person will report the shares held in Zhejiang Haisen Pharmaceutical Co., Ltd. and its changes to Zhejiang Haisen Pharmaceutical Co., Ltd. The shares transferred by the person in each year shall not exceed 25% of the total number of shares held by the person in Zhejiang Haisen Pharmaceutical Co., Ltd. Within 6 months after resignation, the shares of Zhejiang Haisen Pharmaceutical Co., Ltd. held by the person shall not be transferred.
The company shareholder, director and senior manager, Ai Lin promised that, within one year from the date when the shares issued by Zhejiang Haisen Pharmaceutical Co., Ltd. are listed on the stock exchange, the person will not transfer or entrust others to manage the shares of Zhejiang Haisen Pharmaceutical Co., Ltd. currently held, nor will Zhejiang Haisen Pharmaceutical Co., Ltd. repurchase the shares of Zhejiang Haisen Pharmaceutical Co., Ltd. that is currently held by the person. Within 6 months after the listing of Zhejiang Haisen Pharmaceutical Co., Ltd., if the closing price of the company?s stock is lower than the issue price for 20 consecutive trading days or if the closing price at the end of 6 months after listing is lower than the issue price, the lock-up period of the shares held by the person in Zhejiang Haisen Pharmaceutical Co., Ltd. will be automatically extended for 6 months. In case of ex-rights and ex-dividend events, the above issue price shall be adjusted accordingly. During the person?s tenure as director or senior management of Zhejiang Haisen Pharmaceutical Co., Ltd., the person will report the shares held in Zhejiang Haisen Pharmaceutical Co., Ltd. and its changes to Zhejiang Haisen Pharmaceutical Co., Ltd. The shares transferred by the person in each year shall not exceed 25% of the total number of shares held by the person in Zhejiang Haisen Pharmaceutical Co., Ltd. Within 6 months after resignation, the shares of Zhejiang Haisen Pharmaceutical Co., Ltd. held by the person shall not be transferred.